{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:04:31Z","timestamp":1787627071942,"version":"build-2736575974"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"Importance<\/jats:title>Data and educational gaps in populations with skin of color contribute to racial and ethnic disparities in psoriasis treatment. Cohort A of the VISIBLE study includes participants with psoriasis who self-identify as belonging to a racial or ethnic category other than White, across the entire skin-tone spectrum.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate efficacy, quality of life, and adverse event outcomes among participants with moderate to severe psoriasis and skin of color who received guselkumab, 100 mg, for up to 48 weeks.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This ongoing phase 3b, randomized clinical trial at 39 sites in the US and Canada enrolled adults with skin of color and moderate to severe psoriasis (body surface area [BSA] \u226510%; Psoriasis Area and Severity Index [PASI] \u226512; Investigator\u2019s Global Assessment [IGA] \u22653). Data were collected from August 2022 to June 2024.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Randomized participants (3:1) received guselkumab, 100 mg, at weeks 0 and 4, then every 8 weeks, or placebo with crossover to guselkumab at weeks 16 and 20, then every 8 weeks.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Coprimary end points were IGA score of 0 or 1 (IGA 0\/1) and PASI improvement of 90% or more (PASI 90) at week 16 (guselkumab vs placebo). Major secondary end points included IGA 0; PASI 100; percentage changes from baseline in PASI and BSA; changes from baseline in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) symptoms; and at least a 4-point reduction in PSSD itch.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 103 participants (77 randomized to guselkumab; 26 randomized to placebo), 94 (91.3%) completed 48 weeks of treatment. The mean (SD) age overall was 44.1 (12.9) years, and 74 participants (71.8%) were male. At week 16, coprimary end points were achieved by greater proportions of guselkumab- vs placebo-treated participants (IGA 0\/1: 57 of 77 [74.0%] vs 0 of 26; P<\/jats:italic>\u2009&amp;lt;\u2009.001; PASI 90: 44 of 77 [57.1%] vs 1 of 26 [3.8%]; P<\/jats:italic>\u2009&amp;lt;\u2009.001); 25 of 77 (32.5%) vs 0 of 26 achieved IGA 0 (P<\/jats:italic>\u2009&amp;lt;\u2009.001), and 23 of 77 (29.9%) vs 0 of 26 achieved PASI 100 (P<\/jats:italic>\u2009=\u2009.002). DLQI and PSSD symptoms score least-squares mean changes from baseline were \u221212.1 (95% CI, \u221213.1 to \u221210.9) vs \u22122.5 (95% CI, \u22124.4 to \u22120.6) (P<\/jats:italic>\u2009&amp;lt;\u2009.001), and \u221249.4 (95% CI, \u221254.0 to \u221244.9) vs \u22128.2 (95% CI, \u221215.8 to \u22120.6) (P<\/jats:italic>\u2009&amp;lt;\u2009.001), respectively. A 4-point or greater reduction in PSSD itch score was achieved by 48 (66.7%) vs 4 (16.7%) participants with a baseline score of at least 4 (P<\/jats:italic>\u2009&amp;lt;\u2009.001). Efficacy increased and was maintained through week 48, with guselkumab-randomized participants achieving mean percentage improvements in PASI and BSA of more than 94%, and more than 50% of participants achieving complete clearance. Infections were the most common adverse events in the guselkumab (16 [20.8%]) and placebo (3 [11.5%]) groups through week 16, predominantly upper respiratory tract infection and nasopharyngitis.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this randomized clinical trial, after 3 doses of guselkumab, significant skin clearance and quality of life improvements were observed in this cohort of participants with moderate to severe psoriasis and skin of color across the range of objectively measured skin tones. Improvements increased and were maintained through week 48.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT05272150<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.1836","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T11:31:24Z","timestamp":1750851084000},"page":"901","source":"Crossref","is-referenced-by-count":13,"title":["Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones"],"prefix":"10.1001","volume":"161","author":[{"given":"Andrew","family":"Alexis","sequence":"first","affiliation":[{"name":"Department of Dermatology, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"McMichael","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Soung","sequence":"additional","affiliation":[{"name":"Southern California Dermatology Inc, Santa Ana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Choi","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Horsham, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Alkousakis","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Horsham, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Alonso-Llamazares","sequence":"additional","affiliation":[{"name":"Driven Research LLC, Coral Gables, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Shahriari","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut"},{"name":"Central Connecticut Dermatology, Cromwell"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian O.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Nashville Skin Comprehensive Dermatology Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Bhutani","sequence":"additional","affiliation":[{"name":"Synergy Dermatology, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphne","family":"Chan","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Horsham, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Rowland","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Horsham, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Sauder","sequence":"additional","affiliation":[{"name":"Probity Medical Research, Waterloo, Ontario, Canada"},{"name":"Department of Medicine, University of Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Chih-ho","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Dr Chih-ho Hong Medical Inc, Surrey, British Columbia, Canada"},{"name":"Probity Medical Research, Surrey, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Ontario, Canada"},{"name":"FACET Dermatology, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jensen","family":"Yeung","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Jeyarajah","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Ma","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Long","family":"Gao","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Park-Wyllie","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Dermatology, George Washington University School of Medicine, Washington, DC"},{"name":"Aesthetic & Dermatology Center, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lee","sequence":"additional","affiliation":[{"name":"Lee Medical Associates, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Vashi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chesahna","family":"Kindred","sequence":"additional","affiliation":[{"name":"Kindred Hair & Skin Center, Marriottsville, Maryland"},{"name":"Department of Dermatology, Howard University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Grimes","sequence":"additional","affiliation":[{"name":"The Grimes Center for Medical and Aesthetic Dermatology, Vitiligo and Pigmentation Institute of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seemal R.","family":"Desai","sequence":"additional","affiliation":[{"name":"Innovative Dermatology, Plano, Texas"},{"name":"Department of Dermatology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"VISIBLE Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"doi250026r1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.det.2023.02.002","article-title":"Diagnosing psoriasis in skin of color patients.","volume":"41","author":"Khanna","year":"2023","journal-title":"Dermatol Clin"},{"issue":"3","key":"doi250026r2","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40257-017-0332-7","article-title":"Psoriasis in skin of color: insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-white racial\/ethnic groups.","volume":"19","author":"Kaufman","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"10281","key":"doi250026r3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis.","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"doi250026r4","first-page":"16","article-title":"Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances.","volume":"7","author":"Alexis","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"issue":"5","key":"doi250026r5","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00403-022-02507-z","article-title":"Racial disparities in dermatology.","volume":"315","author":"Narla","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"doi250026r6","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.36849\/JDD.7090","article-title":"Evolving concepts in psoriasis: special considerations for patients with skin of color, skin barrier dysfunction, and the role of adjunctive skin care.","volume":"21","author":"Alexis","year":"2022","journal-title":"J Drugs Dermatol"},{"issue":"2S","key":"doi250026r7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.12788\/cutis.0038","article-title":"Psoriasis in patients of color: differences in morphology, clinical presentation, and treatment.","volume":"106","author":"Nicholas","year":"2020","journal-title":"Cutis"},{"issue":"2","key":"doi250026r8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.12788\/cutis.0576","article-title":"Racial disparities in the diagnosis of psoriasis.","volume":"110","author":"Dickerson","year":"2022","journal-title":"Cutis"},{"issue":"2","key":"doi250026r9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/jamadermatol.2016.4129","article-title":"Diversity in dermatology clinical trials: a systematic review.","volume":"153","author":"Charrow","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi250026r10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jaad.2020.04.084","article-title":"Skin color in dermatology textbooks: an updated evaluation and analysis.","volume":"84","author":"Adelekun","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi250026r11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.36518\/2689-0216.1429","article-title":"Presentations of cutaneous disease in various skin pigmentations: plaque psoriasis.","volume":"3","author":"Hermann","year":"2022","journal-title":"HCA Healthc J Med"},{"issue":"3","key":"doi250026r12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1001\/jamadermatol.2024.5103","article-title":"Improving diversity in a novel psoriasis study: VISIBLE as a framework for clinical trial quality improvement.","volume":"161","author":"Alexis","year":"2025","journal-title":"JAMA Dermatol"},{"key":"doi250026r13","first-page":"33","article-title":"Soleil et peau.","volume":"2","author":"Fitzpatrick","year":"1975","journal-title":"J Med Esthet"},{"issue":"6","key":"doi250026r14","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/archderm.1988.01670060015008","article-title":"The validity and practicality of sun-reactive skin types I through VI.","volume":"124","author":"Fitzpatrick","year":"1988","journal-title":"Arch Dermatol"},{"issue":"1","key":"doi250026r15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jid.2019.11.003","article-title":"Research techniques made simple: cutaneous colorimetry: a reliable technique for objective skin color measurement.","volume":"140","author":"Ly","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"8","key":"doi250026r16","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1001\/jamadermatol.2015.0351","article-title":"Fitzpatrick skin type, individual typology angle, and melanin index in an African population: steps toward universally applicable skin photosensitivity assessments.","volume":"151","author":"Wilkes","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi250026r17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","article-title":"The 5-point Investigator\u2019s Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials.","volume":"26","author":"Langley","year":"2015","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"doi250026r18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid.","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"issue":"5","key":"doi250026r19","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/j.1365-2133.2007.08183.x","article-title":"The \u2018handprint\u2019 approximates to 1% of the total body surface area whereas the \u2018palm minus the fingers\u2019 does not.","volume":"157","author":"Thomas","year":"2007","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi250026r20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"doi250026r21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi250026r22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data.","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"issue":"1","key":"doi250026r23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jdds.2015.07.004","article-title":"Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: the Psoriasis Symptoms and Signs Diary.","volume":"20","author":"Feldman","year":"2016","journal-title":"J Dermatol Dermatol Surg"},{"issue":"4","key":"doi250026r24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3109\/09546634.2015.1114567","article-title":"Measurement properties of a patient-reported outcome measure assessing psoriasis severity: the Psoriasis Symptoms and Signs Diary.","volume":"27","author":"Mathias","year":"2016","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"doi250026r25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/09546634.2017.1364694","article-title":"Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial.","volume":"30","author":"Armstrong","year":"2019","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"doi250026r26","first-page":"377","article-title":"Improved quality of life with effective treatment of facial melasma: the PIGMENT trial.","volume":"3","author":"Balkrishnan","year":"2004","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"doi250026r27","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/1346-8138.14172","article-title":"Correlating the Dermatology Life Quality Index and Skin Discoloration Impact Evaluation Questionnaire tools in disorders of hyperpigmentation.","volume":"45","author":"Maymone","year":"2018","journal-title":"J Dermatol"},{"issue":"3","key":"doi250026r28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi250026r29","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"doi250026r30","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1849","article-title":"Guselkumab for moderate to severe scalp psoriasis across all skin tones: the VISIBLE Cohort B randomized clinical trial.","author":"McMichael","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"11","key":"doi250026r31","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s13555-022-00811-0","article-title":"Unmet need in people with psoriasis and skin of color in Canada and the United States.","volume":"12","author":"Yadav","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"doi250026r32","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00403-022-02493-2","article-title":"Dermatologic conditions in skin of color compared to White patients: similarities, differences, and special considerations.","volume":"315","author":"Chatrath","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"doi250026r33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2310\/7750.2009.08077","article-title":"Postinflammatory hyperpigmentation.","volume":"13","author":"Taylor","year":"2009","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"doi250026r34","first-page":"77","article-title":"Racial limitations of Fitzpatrick skin type.","volume":"105","author":"Ware","year":"2020","journal-title":"Cutis"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2835459\/jamadermatology_alexis_2025_oi_250026_1757438057.43233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:00:44Z","timestamp":1758121244000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2835459"}},"subtitle":["Cohort A of the VISIBLE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.1836","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}